You are here: Industry Insights > cancer drug

News List

“Precise” “Broad-spectrum” – An Overview of NTRK Fusion-Targeted Oncology Drugs PharmaSources/Zongqin
June 17, 2020
According to the official website of the CDE recently, InnoCare Pharma’s ICP-723 tablets has received a clinical trial implied permission,
CRUK teams up with Teon to trial first-in-class cancer drug pharmaceutical-technology
March 03, 2021
Cancer Research UK (CRUK) has signed a clinical development collaboration with California-based Teon Therapeutics.
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug prnasia
March 02, 2021
Oscotec Inc., the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement.
Researchers from IIT Madras identify alternative source for anti-cancer drug Camptothecin expresspharma
February 26, 2021
At present, this drug is sourced from Chinese and Indian tree species, which are now critically endangered due to extensive overharvesting to meet the market demand.
Fresenius Kabi Oncology Ltd to pay $50mn for destroying records ahead of an FDA Inspection europeanpharmaceuticalreview
February 19, 2021
The Indian drug company pleaded guilty to concealing and destroying records containing evidence of its Kalyani plant manufacturing drugs in contravention to FDA requirements prior to a 2013 inspection.
Celleron picks up discarded cancer drug from Roche pharmatimes
August 14, 2020
Oxford, UK-based Celleron Therapeutics has signed a licensing agreement with Roche for exclusive rights to emactuzumab, a monoclonal antibody and tumour microenvironment modulator.
ICR/Cyclacel scientists discover new cancer drug pharmatimes
July 16, 2020
Researchers say they have discovered a new cancer drug with potential use against a range of cancers, including some blood cancers and solid tumours.
Roche signs up to $1.7bn cancer drug deal with Blueprint Medicines pharmaceutical-technolog
July 15, 2020
Roche has entered into a licensing and collaboration agreement with Blueprint Medicines for exclusive rights to co-develop and commercialise the latter’s cancer drug, pralsetinib, outside the US, except in Greater China.
Ruxolitinib to be studied as COVID-19 treatment in clinical trial europeanpharmaceuticalreview
June 24, 2020
Following the successful treatment of a COVID-19 patient with ARDS using ruxolitinib, Germany is set to begin clinical trials to test the drug.
How a Seattle Genetics cancer drug could help lupus patients fiercebiotech
April 13, 2020
The kidney is often a target of autoimmune diseases, including lupus. But little is known about how immune cells adapt to the low oxygen level in renal tissue to wreak havoc.

Previous page 1 2 3 4 5 6 Next page